1606 Corp. Target for Strategic Investment Adnexus Biotechnologies Merges With Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments
1606 Corp (OTC PINK:CBDW) announces that its investment target Adnexus Biotechnologies has completed a merger agreement to acquire Sanctum Therapeutics' core technology assets for HIV and SARS-CoV-2 treatments. The merger combines Adnexus's AI-driven drug discovery platform with Sanctum's long-acting HIV capsid inhibitor and Adnexus's anti-HIV monoclonal antibodies. 1606 Corp has executed a Letter of Intent for a 5% strategic investment in Adnexus, with the LOI terminating on November 27, 2024.
1606 Corp (OTC PINK:CBDW) annuncia che il suo obiettivo di investimento, Adnexus Biotechnologies, ha completato un accordo di fusione per acquisire i principali beni tecnologici di Sanctum Therapeutics per i trattamenti contro l'HIV e il SARS-CoV-2. La fusione combina la piattaforma di scoperta di farmaci basata sull'IA di Adnexus con l'inibitore del capsidi per l'HIV a lunga durata di Sanctum e gli anticorpi monoclonali anti-HIV di Adnexus. 1606 Corp ha firmato una Lettera di Intenti per un investimento strategico del 5% in Adnexus, con la LOI che scade il 27 novembre 2024.
1606 Corp (OTC PINK:CBDW) anuncia que su objetivo de inversión, Adnexus Biotechnologies, ha completado un acuerdo de fusión para adquirir los activos tecnológicos clave de Sanctum Therapeutics para tratamientos de VIH y SARS-CoV-2. La fusión combina la plataforma de descubrimiento de fármacos impulsada por IA de Adnexus con el inhibidor de cápside de VIH de acción prolongada de Sanctum y los anticuerpos monoclonales anti-VIH de Adnexus. 1606 Corp ha ejecutado una Carta de Intención para una inversión estratégica del 5% en Adnexus, con la LOI que finaliza el 27 de noviembre de 2024.
1606 Corp (OTC PINK:CBDW)가 투자 목표인 Adnexus Biotechnologies가 HIV 및 SARS-CoV-2 치료를 위한 핵심 기술 자산을 Sanctum Therapeutics로부터 인수하는 합병 계약을 완료했다고 발표했습니다. 이번 합병은 Adnexus의 AI 기반 신약 발견 플랫폼과 Sanctum의 장기 작용 HIV 캡시드 억제제, 그리고 Adnexus의 항-HIV 단클론 항체를 결합합니다. 1606 Corp는 Adnexus에 대한 5%의 전략적 투자에 대한 의향서를 체결하였으며, LOI는 2024년 11월 27일에 종료됩니다.
1606 Corp (OTC PINK:CBDW) annonce que son objectif d'investissement, Adnexus Biotechnologies, a conclu un accord de fusion pour acquérir les principaux actifs technologiques de Sanctum Therapeutics pour les traitements du VIH et du SARS-CoV-2. La fusion combine la plateforme de découverte de médicaments assistée par IA d'Adnexus avec l'inhibiteur de capsides du VIH à action prolongée de Sanctum et les anticorps monoclonaux anti-VIH d'Adnexus. 1606 Corp a signé une Lettre d'Intention pour un investissement stratégique de 5 % dans Adnexus, la LOI expirant le 27 novembre 2024.
1606 Corp (OTC PINK:CBDW) gibt bekannt, dass das Investitionsziel Adnexus Biotechnologies eine Fusionsvereinbarung zur Übernahme der zentralen Technologieressourcen von Sanctum Therapeutics für HIV- und SARS-CoV-2-Behandlungen abgeschlossen hat. Die Fusion verbindet die KI-gesteuerte Medikamentenentdeckungsplattform von Adnexus mit Sanctums langwirkendem HIV-Capsid-Hemmer und den anti-HIV-Monoklonalen Antikörpern von Adnexus. 1606 Corp hat ein Letter of Intent für eine strategische Investition von 5% in Adnexus unterzeichnet, wobei das LOI am 27. November 2024 endet.
- Strategic merger combines complementary HIV treatment technologies
- Integration of AI-driven drug discovery platform with established therapies
- Potential expansion in the HIV treatment market
- Dual-action treatment approach may reduce viral resistance
- LOI for strategic investment has short termination date (November 27, 2024)
- Investment to 5% stake in Adnexus
- No disclosed financial terms of the merger
SEATTLE, WA / ACCESSWIRE / November 12, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606"), a leader in AI technology, acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise. The combination of resources and expertise significantly enhance the research capabilities of Adnexus's HIV and SARS-CoV-2 research.
Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics' leading-edge assets. This strategic merger combines Adnexus's state-of-the-art AI-driven drug discovery platform with Sanctum's innovative long-acting HIV capsid inhibitor and Adnexus's short-acting anti-HIV monoclonal antibodies. Together, these therapies offer a potent, dual-action approach that enhances treatment efficacy, reduces the risk of viral resistance, and provides a promising new option for HIV patients.
The acquisition further strengthens Adnexus's position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases. With Sanctum's advanced inhibitors and expertise in navigating the FDA regulatory landscape, Adnexus is uniquely positioned to accelerate the development of high-impact therapies.
Austen Lambrecht, CEO of 1606 Corp., commented, "The merger between Adnexus Biotechnologies and Sanctum Therapeutics marks a pivotal moment in the fight against HIV and other infectious diseases. By combining Adnexus's cutting-edge AI-driven drug discovery platform with Sanctum's breakthrough therapies, they are not only advancing the development of life-saving treatments but also driving forward our mission to leverage technological innovation for the betterment of global healthcare. Lambrecht continued, "This strategic partnership underscores our commitment to supporting transformative biotech advancements, and we are excited to play a role in helping bring these therapies to market for those who need them most."
This synergistic combination of resources, along with Adnexus's cutting-edge Sutra AI Drug Discovery Platform, creates a powerful foundation for continued innovation and growth, ultimately delivering significant value for patients and shareholders alike.
Adnexus has recently executed a Letter of Intent with the Company for a strategic investment by the Company for
About Adnexus Biotechnologies Inc.
Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.
About 1606 Corp.
1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.
For more information, please visit cbdw.ai
Industry Information
The global AI market, valued at
Forward-Looking Statements
This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. The Company does not undertake any obligation to update forward-looking statements except as required by law.
For inquiries, please contact our CEO, Austen Lambrecht, at austen@1606corp.com.
Contact Information:
Austen Lambrecht
CEO
austen@1606corp.com
SOURCE: 1606 Corp.
View the original press release on accesswire.com
FAQ
What is the purpose of Adnexus Biotechnologies' merger with Sanctum Therapeutics?
What is 1606 Corp's (CBDW) involvement in the Adnexus-Sanctum merger?
What key technologies are being combined in the Adnexus-Sanctum merger?
